Unmet Need in CNS
Scientific Founders & Advisors
Welcome to Q Therapeutics
Advanced cellular therapeutics
for incurable CNS diseases
The hope of potential future treatment
A revolutionary approach based on non-neuronal cells
Our first clinical trial for amyotrophic lateral sclerosis
Anticipated to commence in 2015
Our Unique Approach
Q Therapeutics has adopted a unique approach to developing human cell-based therapies for debilitating – and currently incurable – diseases of the brain and spinal cord (the central nervous system, or CNS). Our revolutionary approach focuses on glial cells – non-neuronal cells in the CNS that are essential for supporting, repairing and maintaining normal neuron function and health.
Lead Therapeutic Candidate
– our first cellular therapeutic candidate – are human glial progenitor cells that give rise to two types of specialized glial cells, astrocytes and oligodendrocytes. In pre-clinical studies, Q-Cells
have been shown to successfully replicate, migrate and differentiate at sites of CNS injury and disease, with resulting improvements in both function and survival, and no observed toxicity.
Transitioning into the Clinic
Q Therapeutics is now transitioning to a clinical-stage company, with a first-in-human phase 1/2a clinical trial planned in patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease).